COPD Drug Market Opportunity and Clinical Pipeline Analysis
ReportsnReports.com offers COPD Drug Market Opportunity & Clinical Pipeline Analysis 2014 to 2018 industry research report in its store at http://www.reportsnreports.com/reports/280894-copd-drug-market-opportunity-clinical-pipeline-analysis.html .
Trending on the Topix Network
Fri Apr 18, 2014
The Motley Fool
In Case You Missed It: GlaxoSmithKline Just Had a Phenomenal Week
Of course, Glaxo's week was also marred by allegations in five countries -- Poland, Iraq, Jordan, Lebanon, and China -- that it paid bribes to doctors.
Thu Apr 17, 2014
Exercise helps COPD patients avoid hospital readmission
Patients with chronic obstructive pulmonary disease who participated in moderate to vigorous physical activity had a lower risk of hospital readmission within 30 days compared with those who were inactive, according to a study.
Mon Apr 14, 2014
Orion receives first marketing authorisations for Bufomix Easyhaler product
ORION CORPORATION STOCK EXCHANGE RELEASE 14 APRIL 2014 at 9:30 PM EEST Orion receives first marketing authorisations for Bufomix Easyhaler product Orion Corporation has received Irish and Hungarian marketing authorisation for Bufomix Easyhaler , an inhaled budesonide-formoterol combination product indicated for asthma and chronic obstructive ... (more)
Wed Apr 09, 2014
Physical activity associated with lower rates of hospital readmission in patients with COPD
Patients with chronic obstructive pulmonary disease who participated in any level of moderate to vigorous physical activity had a lower risk of hospital readmission within 30 days compared to those who were inactive, according to a study published today in the Annals of the American Thoracic Society .
Coming Up At Robinson Memorial Hospital in Ravenna
Childbirth Education Breastfeeding Class: This class provides expectant mothers with information on the benefits of breast-feeding and how to make their experience a positive one for mother and baby.
Tue Apr 08, 2014
Domainex Announces Promising Results For Cytokine Inhibitors Program
Domainex Ltd. announced the successful completion of a series of laboratory studies evaluating its proprietary selective inhibitors of IKK-epsilon and TBK1 in inflammation studies.
Mon Apr 07, 2014
Domainex Programme Shows Great Promise for the Treatment of Inflammatory Diseases, Such as ...
Domainex Ltd ., today announced that it has successfully completed a series of laboratory studies examining the in vivo effects of its proprietary selective inhibitors of IKK-epsilon and TBK1 in inflammation models.
Fri Apr 04, 2014
Vertex Venture Holdings leads $42 mln Series D funding in Holaira
Vertex Venture Holdings has led a $42 million Series D funding round in Holaira, Inc. , a developer of medical devices to treat obstructive lung diseases.
Thu Apr 03, 2014
Med-tech startup fighting lung disease raises $42M
Vertex Venture Holdings , a subsidiary of Singapore investment firm Temasek Holdings , led the round of investment in Plymouth-based Holaira Inc. Windham Venture Partners, Holaira's previous investors, and two unnamed strategic investors also participated.
Mon Mar 31, 2014
Theravance: Baby Thrown Out With The Bath Water - 35% To 65% Upside
Blue chip investors have recently bought more THRX shares 20-25% higher than the current price.
Long-acting inhaled therapy (beta-agonists, anticholinergics and...
Pharmacological therapy for chronic obstructive pulmonary disease is aimed at relieving symptoms, improving quality of life and preventing or treating exacerbations.Treatment tends to begin with one inhaler, and additional therapies are introduced as necessary.